MY195679A - Pyrimidin-2-Ylamino-1h-Pyrazols as Lrrk2 Inhibitors for use in the Treatment of Neurodegenerative Disorders - Google Patents
Pyrimidin-2-Ylamino-1h-Pyrazols as Lrrk2 Inhibitors for use in the Treatment of Neurodegenerative DisordersInfo
- Publication number
- MY195679A MY195679A MYPI2018002395A MYPI2018002395A MY195679A MY 195679 A MY195679 A MY 195679A MY PI2018002395 A MYPI2018002395 A MY PI2018002395A MY PI2018002395 A MYPI2018002395 A MY PI2018002395A MY 195679 A MY195679 A MY 195679A
- Authority
- MY
- Malaysia
- Prior art keywords
- pyrazols
- ylamino
- pyrimidin
- treatment
- neurodegenerative disorders
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662417151P | 2016-11-03 | 2016-11-03 | |
PCT/US2017/037782 WO2017218843A1 (en) | 2016-06-16 | 2017-06-15 | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders |
US201962350876P | 2019-07-11 | 2019-07-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
MY195679A true MY195679A (en) | 2023-02-03 |
Family
ID=87569417
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI2018002395A MY195679A (en) | 2016-11-03 | 2017-06-15 | Pyrimidin-2-Ylamino-1h-Pyrazols as Lrrk2 Inhibitors for use in the Treatment of Neurodegenerative Disorders |
Country Status (1)
Country | Link |
---|---|
MY (1) | MY195679A (en) |
-
2017
- 2017-06-15 MY MYPI2018002395A patent/MY195679A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SA521430638B1 (en) | Pyrimidin-2-Ylamino-1h-Pyrazols as Lrrk2 Inhibitors for Use in The Treatment of Neurodegenerative Disorders | |
PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
MX2021009673A (en) | Modulators of ror-gamma. | |
CR20200054A (en) | Compounds, compositions and methods | |
PH12017500583A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
PH12016501457A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
MD20170016A2 (en) | Aminopyrimidinyl compounds as JAK inhibitors | |
EP4282479A3 (en) | Use of pridopidine to treat depression or anxiety | |
PH12017500595B1 (en) | Aldosterone synthase inhibitors | |
MX2016009621A (en) | Furo-3-carboxamide derivatives and methods of use. | |
MY178971A (en) | Triaminopyrimidine compounds useful for preventing or treating malaria | |
MX2020005707A (en) | Creatine prodrugs, compositions and methods of use thereof. | |
EA201892532A1 (en) | Pyrimidine-2-Ilamino-1H-Pyrazoles as an LRRK2 inhibitor for use in the treatment of neurodegenerative diseases | |
MY195679A (en) | Pyrimidin-2-Ylamino-1h-Pyrazols as Lrrk2 Inhibitors for use in the Treatment of Neurodegenerative Disorders | |
MY183757A (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | |
NZ747201A (en) | (+)-azasetron for use in the treatment of ear disorders | |
MX2023012107A (en) | Pyridostigmine for use in the treatment of covid-19. |